Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment

被引：0
|
作者：
Rocca, S. [1 ]
Hansbarger, M. [1 ]
Gill, T. [1 ]
George, E. [2 ]
Rom, I. [1 ]
Weinstein, J. [1 ]
Breslin, H. [3 ]
Jia, L. [3 ]
Simpkins, F. [4 ]
Brown, E. [5 ,6 ]
Gilad, O. [7 ]
机构：
[1] Aprea Therapeut Inc, Biol, Doylestown, PA USA
[2] Moffit Canc Ctr, Gynecol Oncol Program, Tampa, FL USA
[3] Aprea Therapeut Inc, Med Chem, Doylestown, PA USA
[4] Univ Penn, Dept Obstet & Gynecol, Perelman Sch Med, Ovarian Canc Res Ctr,Div Gynecol Oncol, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
[6] Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[7] Aprea Therapeut Inc, Co Management, Doylestown, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114849
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB324
引用
收藏
页码：S126 / S127
页数：2
相关论文
共 50 条
  • [1] First-in-class TRPV6 inhibitors for the treatment of prostate cancer
    Beaumont, Kimberley
    Pouwer, Rebecca
    Rahmani, Raphael
    McLachlan, Matthew
    Levrier, Claire
    Farrow, Rebecca
    Yeh, Mei
    Johnson, Therese
    Kumarasiri, Malika
    Wijesekera, Hasanthi
    Stuchbury, Grant
    Cock, Terrie-Anne
    Harvey, Andrew
    Monteith, Gregory
    Dymock, Brian
    CANCER RESEARCH, 2023, 83 (11)
  • [2] Fidaxomicin: first-in-class macrocyclic antibiotic
    Mullane, Kathleen M.
    Gorbach, Sherwood
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (07) : 767 - 777
  • [3] First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer
    Sapetschnig, Alexandra
    Thomas, Beth
    Yankova, Eliza
    Fischl, Harry
    Azevedo, Aleksandra
    Bucknell, Sarah
    Fosbeary, Richard
    Sawyer, Sapphire
    Evans, Sian
    Livi, Carmen
    Andrews, Byron
    Rogan, Jack
    Webster, Natalie
    Fyfe, Matthew
    Tzelepis, Konstantinos
    Rausch, Oliver
    CANCER RESEARCH, 2024, 84 (07)
  • [4] Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer
    Fang, Wei
    Zheng, Jianwei
    Deng, Lin
    An, Yana
    Rong, Deqin
    Wei, Jianwei
    Xiong, Xiao-Feng
    Wang, Junjian
    Wang, Yuanxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) : 1481 - 1499
  • [5] First-in-class allosteric inhibitors of bacterial IMPDHs
    Alexandre, Thomas
    Lupan, Alexandru
    Helynck, Olivier
    Vichier-Guerre, Sophie
    Dugue, Laurence
    Gelin, Muriel
    Haouz, Ahmed
    Labesse, Gilles
    Munier-Lehmann, Helene
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 167 : 124 - 132
  • [6] First-in-class orally active pharmacological inhibitors of TRPV6 for the treatment of advanced prostate cancer
    Monteith, Gregory
    Beaumont, Kimberley
    Pouwer, Rebecca
    Farrow, Rebecca
    McLachlan, Matthew
    Yeh, Mei
    Johnson, Therese
    Rahmani, Raphael
    Levrier, Claire
    Wijesekera, Hasanthi
    Kumarasiri, Malika
    Stuchbury, Grant
    Cock, Terrie-Anne
    Harvey, Andrew
    Dymock, Brian
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [7] Discovery and development of first-in-class orally bioavailable USP19 inhibitors
    Jacq, Xavier
    Gavory, Gerald
    O'Dowd, Colin
    Cranston, Aaron
    Baker, Oliver
    Bell, Christina
    Burton, Stephanie
    Cassidy, Eamon
    Costa, Joana
    Henderson, Ashling
    Helm, Matthew
    Hewitt, Peter
    Hughes, Caroline
    McFarland, Mary
    Miel, Hugues
    Proctor, Lauren
    Roundtree, Shane
    Church, Rachel
    Rozycka, Ewelina
    Wappett, Mark
    Whitehead, Steven
    Harrison, Tim
    Bedard, Nathalie
    Wing, Simon S.
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Imiqualines for pancreatic cancer: first-in-class potent and synergistic inhibitors of microtubule polymerisation
    Bigot, Kevin
    Garambois, Veronique
    Vie, Nadia
    Bruciamacchie, Marine
    Colombo, Pierre-Emmanuel
    Tosi, Diego
    Patinote, Cindy
    Maggipinto, Yann
    Bonnet, Pierre-Antoine
    Gongora, Celine
    Deleuze-Masquefa, Carine
    Larbouret, Christel
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer
    Foote, Kevin M.
    Lau, Alan
    Nissink, J. Willem M.
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (07) : 873 - 892
  • [10] A first-in-class therapy for the treatment of advanced stage liver cancer.
    Brookes, Steve
    Levy, Gary
    Seo, Jin
    Cutler, Murray
    Adamson, Gord
    Bell, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345